{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shulman LN"],"funding":["NCI NIH HHS"],"pagination":["2311-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4105484"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(22)"],"pubmed_abstract":["<h4>Purpose</h4>Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered less toxicity.<h4>Patients and methods</h4>Patients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to address the noninferiority of single-agent T to AC, defined as the one-sided 95% upper-bound CI (UCB) of hazard ratio (HR) of T versus AC less than 1.30 for the primary end point of relapse-free survival (RFS). As a 2 × 2 factorial design, duration of therapy was also addressed and was previously reported.<h4>Results</h4>With 3,871 patients enrolled on"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)."],"pmcid":["PMC4105484"],"funding_grant_id":["N01 CA032102","U10 CA045418","U10 CA047559","U10 CA032102","U10 CA077651","U10 CA025224","U10 CA077658","U10 CA047577","CA77658","CA77651","CA21115","U10 CA180838","U10 CA032291","U10 CA021115","CA33601","CA31946","U10 CA031946","U10 CA180882","P30 CA016672","UG1 CA233180","U10 CA180820","P30 CA015083","CA25224","CA47577","U10 CA180867","CA3360","U10 CA033601","U10 CA180821","CA47559","U10 CA180888","CA45418","CA32291"],"pubmed_authors":["Norton L","Shulman LN","Schneider CJ","O'Regan R","Perez EA","Shapiro CL","Berry DA","Becker HP","Winer EP","Cirrincione CT","Hudis CA","Burstein HJ","Muss H","Martino S","Kimmick G"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).","description":"<h4>Purpose</h4>Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered less toxicity.<h4>Patients and methods</h4>Patients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to address the noninferiority of single-agent T to AC, defined as the one-sided 95% upper-bound CI (UCB) of hazard ratio (HR) of T versus AC less than 1.30 for the primary end point of relapse-free survival (RFS). As a 2 × 2 factorial design, duration of therapy was also addressed and was previously reported.<h4>Results</h4>With 3,871 patients enrolled on","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Aug","modification":"2026-04-29T08:59:00.638Z","creation":"2019-03-27T01:32:29Z"},"accession":"S-EPMC4105484","cross_references":{"pubmed":["24934787"],"doi":["10.1200/JCO.2013.53.7142","10.1200/jco.2013.53.7142"]}}